Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

125.86
Delayed Data
As of 4:00pm ET
 -2.36 / -1.84%
Today’s Change
110.56
Today|||52-Week Range
193.45
-34.02%
Year-to-Date
5 Growth Stocks to Buy in September
10:55am / MotleyFool.com - Paid Partner Content
New Strong Sell Stocks for August 22nd
Aug 22 / Zacks.com - Paid Partner Content
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Aug 30 / Zacks.com - Paid Partner Content
New Strong Sell Stocks for August 22nd
Aug 22 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug 24 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close128.22
Today’s open127.77
Day’s range125.69 - 128.72
Volume1,371,354
Average volume (3 months)1,790,310
Market cap$28.8B
Dividend yield--
Data as of 4:00pm ET, 08/31/2016

Growth & Valuation

Earnings growth (last year)-79.45%
Earnings growth (this year)-6.51%
Earnings growth (next 5 years)+24.20%
Revenue growth (last year)+12.25%
P/E ratio419.5
Price/Sales16.57
Price/Book3.50

Competitors

 Today’s
change
Today’s
% change
BAXBaxter International...-0.03-0.06%
ZTSZoetis Inc+0.35+0.69%
VRTXVertex Pharmaceutica...-1.29-1.35%
MYLMylan NV-0.39-0.91%
Data as of 4:02pm ET, 08/31/2016

Financials

Next reporting dateOctober 20, 2016
EPS forecast (this quarter)$1.19
Annual revenue (last year)$2.5B
Annual profit (last year)$144.4M
Net profit margin5.81%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
David L. Hallal
Executive Vice President-
Global Operations
Julie O'Neill
Corporate headquarters
Cheshire, Connecticut

Forecasts

Search for Jobs